New Study Demonstrates AI-Powered Care Coordination Reduces Transfer Time and Improves Outcomes in Intracerebral Hemorrhage Patients
SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data showcasing the impact of Viz ICH and Viz ICH Plus in optimizing care for patients with intracerebral hemorrhage (ICH). The study, ' Optimizing Intracerebral Hemorrhage Management and Interhospital Transfer With Viz ICH Plus AI Technology,' highlights how AI-powered detection and quantification significantly reduced interhospital transfer (IHT) time, expediting treatment and improving patient outcomes.
The case study features a 47-year-old patient with a right parieto-occipital hematoma who was rapidly identified by Viz.ai and transferred through the Neuroemergencies Management and Transfer (NEMAT) program. The use of Viz ICH and Viz ICH Plus cut the interhospital transfer time nearly in half - from an average of 200 minutes to just 101 minutes in this case - allowing the patient to undergo successful surgical evacuation and experience significant neurological recovery over the following year.
'Viz ICH has transformed how we identify and triage patients with ICH,' said Christopher Kellner, MD, Director of the Intracerebral Hemorrhage Program at Mount Sinai. 'By accelerating diagnosis and enabling real-time alerts across teams and hospitals, this technology streamlines the entire transfer process, ensuring patients get the care they need without unnecessary delays.'
Intracerebral hemorrhage accounts for up to 15% of all strokes and has high morbidity and mortality rates, requiring rapid diagnosis and intervention. Accurate volume measurements of brain bleeds are crucial for assessing the severity of cases, monitoring progression, and guiding treatment decisions. However, these measurements have traditionally been manual and time consuming. Radiologists, neurologists and neurosurgeons can incorporate Viz ICH and Viz ICH Plus seamlessly into their workflows to automate this process and support faster, more efficient care decisions.
In addition to reducing transfer time, AI-powered detection and quantification has demonstrated improved efficiency in clinical workflows, with faster hematoma volume estimation and more accurate assessments compared to manual methods. The study also highlights the scalability of the solution across large, complex hospital systems where specialized ICH care may only be available at select sites.
'At Viz.ai, we are committed to using AI to close the gaps in stroke care and bring faster, more accurate treatment to every patient—no matter where they first present,' said Molly Madziva Taitt, Ph.D., VP of Global Clinical Affairs at Viz.ai. 'This study is a powerful example of how AI can reduce delays, support earlier interventions, and ultimately improve outcomes for patients with intracerebral hemorrhage.'
To learn more about Viz ICH Plus, visit viz.ai/hyperdensity-measurements.
About Viz.ai, Inc.
Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One® is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit Viz.ai.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
an hour ago
- Miami Herald
See How the Rivian R2's Advanced Suspension Elevates Your Drive
Expected to become available in early 2026, Rivian's upcoming R2 is a midsize, fully electric SUV that will slot beneath the R1S and R1T in the automaker's lineup and will provide a more rugged alternative to established electric crossovers such as the Tesla Model Y and the Ford Mustang Mach E. As we eagerly await the arrival of Rivian's third-ever model, we can now take a closer look at the R2's innovative suspension system, as shared on Instagram by the brand's founder and CEO, RJ Scaringe. According to Scaringe's Instagram post, the "R2 multi-link rear suspension includes 5 stamped steel links and uses an isolated rear subframe to deliver incredible ride quality and handling." In an automotive first, the Rivian R2's rear suspension resembles a "starfish" in an effort to "reduce unsprung mass to support enhanced ride quality." Judging by the comments on RJ's Instagram post, it seems that people are generally very excited by the innovative suspension system. Perhaps most importantly, the brand CEO's fascination with seemingly small details such as the R2's rear suspension system echoes the automaker's attention to detail, which seems to have resonated with buyers and enthusiasts alike. Featuring two unique battery sizes, the Rivian R2 will reportedly be available with over 300 miles of all-electric range and a 0-60 miles per hour time of under three seconds. Perhaps the most notable feature of the Rivian R2 is its size. Claimed to be a true SUV, rather than a crossover, the modest-yet-ample sizing of the Rivian R2 reminds us of a popular segment of SUVs that, into the late-2000s and early-2010s, saw most of its models morph into softer, less-rugged crossovers, such as the Jeep Cherokee, the Ford Explorer, and the Chevrolet Blazer. Now that boxy and rugged-yet-practical SUVs are regaining popularity, Rivian is set to be ahead of the game by offering a vehicle in a class that seems to have been entirely neglected for far too long, even by more traditional combustion-powered options. While the upcoming Rivian R2 seems like it's set to be one of the most exciting and most usable electric SUVs introduced to date, perhaps the most eagerly anticipated feature is the R2's supposed price tag, which is expected to start around $45,000 USD. That's about the same price as a 2025 Ford Explorer ST-Line, a Toyota Highlander Hybrid, or a Tesla Model Y without the federal EV tax incentive included, despite offering superior interior spaciousness and rugged, off-road-ready chops. We're eagerly awaiting the Rivian R2's imminent arrival in early 2026, and we're excited to see how it stacks up against more established EV SUVs. Copyright 2025 The Arena Group, Inc. All Rights Reserved.
Miami Herald
2 hours ago
- Miami Herald
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series
Click here to register Discussion will focus on company's May 2025 meeting with the FDA to review the statistically significant responder analysis results for the subgroup of breast cancer patients in company's recently conducted Phase 3 OnTarget trial The currently estimated US metastatic breast cancer population potentially qualifies as an orphan population, in alignment with company's core focus on orphan diseases Company plans to promptly pursue authorization to initiate expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / June 9, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today issued a reminder that Lisa Conte, the company's founder, president and CEO, will participate in a virtual fireside chat at 9:00 AM Eastern tomorrow, Tuesday, June 10, 2025, as part of Lytham Partners' spring 2025 Spotlight Series. Participation Instructions for Jaguar Health's Virtual Fireside Chat During Lytham Partners Spring 2025 Spotlight Series When: Tuesday, June 10, 2025 from 9:00 - 10:00 AM Eastern Where: Online (Click Here). The fireside chat will also be available for replay following the event. About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will participate in a virtual fireside chat June 10, 2025 as part of Lytham Partners' spring 2025 Spotlight Series, Jaguar's expectation that the currently estimated US metastatic breast cancer population may qualify as an orphan population, and Jaguar's expectation that it will promptly pursue authorization to initiate an expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer patients. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Source: Jaguar Health, Inc. Contact: hello@ Jaguar-JAGX SOURCE: Jaguar Health, Inc.
Yahoo
2 hours ago
- Yahoo
Nicholas Academic Centers Celebrates Class of 2025 With Stories of Grit, Growth, and Giving Back
SANTA ANA, Calif., June 09, 2025--(BUSINESS WIRE)--One of the four featured Nicholas Academic Centers (NAC) scholars was not expected to survive childbirth. "Before I opened my eyes to this world, I shared my first eight months of life alongside cancer," stated Tanesha Bravo. Injecting her grandmother with insulin, caring for her mother's medical issues, losing her best friend to leukemia, and surviving her own surgeries to remove a hemangioma fueled Bravo's goal of becoming a surgical oncologist. This fall, she heads to Chapman University on a full scholarship as a biochemistry and molecular biology major. Her path has been shaped by the fragility and power of life, inspired by her mother's unwavering strength as she battled illness while working long hours to support her children. An immigrant at age 12, Bravo helped her mom deliver groceries and food while maintaining top grades. The NAC, which provides highly qualified staff, academic assistance and tutoring, social services, cultural enrichment programs, college access and support services, and need-based scholarship opportunities for students, became her second home, providing the guidance and resources she needed to turn a once-distant dream into reality. "I was given a second chance at life," Bravo said. "I couldn't have achieved everything without the NAC, and now I want to be that support for others." On June 6, 2025, Broadcom cofounder Dr. Henry T. Nicholas III hosted the NAC, elected officials, and community members at the 17th annual NAC graduation ceremony to honor the Class of 2025, 198 graduates who collectively earned 1,736 college acceptances, as they advance to prestigious colleges. NAC Alumni Santa Ana Unified School District (SAUSD) Board Clerk Valerie Magdaleno (Class of 2016) and law student Lisbeth Rosales (Class of 2018) gave encouraging words to the NAC Class of 2025 and the community at the graduation ceremony. The NAC is generously funded by the Henry T. Nicholas III Education Foundation and was founded by Dr. Nicholas and Retired Superior Court Judge Jack Mandel in 2007. Dr. Nicholas has donated $57.7 million to support the three NAC locations in downtown Santa Ana, Valley High School, and Century High School. "Seventeen years later, we are a community that has changed for the better, with more and more students not just getting their bachelor's degrees, but also going on to get their master's, and some even their PhD," said Rodolfo Duarte, Executive Director of the NAC and a fellow NAC alumnus, who jokes about having spent half of his life at the NAC. During long nights studying at the NAC which served as her anchor, Stephania Salvador, the daughter of Mexican immigrants, her father a restaurant server, her mother a catering worker, often thought about her parents' sacrifices, including her father leaving college to provide for the family. A natural leader, Salvador served as senior class president. She also founded a volunteer club and used a $5,000 grant to run a sports camp for special needs children. She is University of Pennsylvania bound on a full scholarship to become a real estate lawyer. "I want to help solve the housing crisis, especially for low-income communities like mine," she explained. Salvador hopes to support her parents and uplift her community through her legal career. Adrian Ramirez discovered early on that reading and analyzing history helped him make sense of the present and imagine a better future. He started at the NAC with a goal to simply get into any college to honor his Mexican-born parents' sacrifices and wishes; NAC expanded his horizon to Harvard University on a full scholarship, where he will major in government, with plans to become an attorney. Ramirez served as president of the National Honor Society, led book drives for local libraries, and promoted civic engagement through Santa Ana Youth Votes. He also spread joy through Origami for Good, creating origami art to donate to children at hospitals, the elderly, and soldiers. Ramirez thanks Dr. Nicholas for "creating a program that showed me that I'm capable of doing so much more than I can even imagine." UC Berkeley-bound Bryan Figueroa dreams of returning to Santa Ana to help his community the way "Dr. Nick has," who "believed in the NAC scholars when they didn't always believe in themselves." The son of a carpenter and a house cleaner, one of Figueroa's first memories was being pushed in a stroller by his mother and collecting cans and bottles to make a few extra dollars. Fueled by these moments, he made a quiet promise to carry their dreams forward. In a full-circle moment, he joined his high school's recycling club. Figueroa has also mentored younger generations through Big Brothers Big Sisters and volunteered for other nonprofits. He plans to major in mathematics to build a career that can support both his family and the community. "The NAC flipped a switch that college was possible," he reflected. "I realized this wasn't just about me. It was about honoring my family's sacrifices." NAC Class of 2025 Highlights: 100% high school graduation (national average of 87%) 100% enrolled directly into college 88% enrolled directly into four-year institutions 96% first-generation college students 95% Latino students NAC Alumni Highlights: A total of 2,498 NAC graduates have earned over $154.2 million in scholarships and grants 95% Latino, 3% Asian American, 2% Other 96% are first-generation college students 75% have enrolled directly into four-year institutions 93% who enrolled in four-year universities have graduated or currently remain enrolled (national average retention rate of 78%) 55% who attended four-year universities graduated in four years (California average of 50%; national Latino average of 32%) 86% who attended four-year universities graduated in six years (national average of 64%; national Latino average of 54%) 13% who completed a bachelor's degree also completed/enrolled in a graduate degree program (national Latino average of 7%) 17th Annual NAC Booklet Press Packet View source version on Contacts MEDIA INQUIRIES: Susan Kang GroupSusan@ (714) 299-0322 Sign in to access your portfolio
